$INVVY News

Last published 3y ago

3y agoINDV INVVYIndivior Enters an Exclusive Licensing Agreement with Alar PharmaceuticalsPR Newswire- Alar's Lead Asset ALA-1000 Potentially is the First Three-Month LAI Treatment for OUD - RICHMOND, Va., Oct. 11, 2023 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV), a leading addiction treatment company, today
3y agoINDV INVVYIndivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in CanadaPR NewswireRates of non-fatal overdose events following SUBLOCADE treatment was lower compared to daily opioid agonist therapy.Data published in the Journal of Addition MedicineRICHMOND, Va., Sept. 26, 2023 /PRNewswire/ -- Indivior
3y agoINDV INVVYIndivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation ClaimsPR NewswireRICHMOND, Va., Aug. 21, 2023 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV), a leading addiction treatment company, announced that its subsidiary, Indivior Inc. (the "Company"), has reached an agreement
3y agoINDV INVVYIndivior Announces Q2/H1 2023 Financial ResultsPR NewswireSLOUGH, United Kingdom, and RICHMOND, Va., July 27, 2023 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced its financial results for the period ending June 30, 2023. The earnings release, investor presentation
3y agoINDV INVVYIndivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug DependencePR NewswireRICHMOND, Va., June 14, 2023 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today announced the acceptance of four abstracts for presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug
3y agoINVVYIndivior to Commence Trading on NasdaqPR NewswireCompany to Ring Opening Bell June 14 to Bring Awareness to Addiction Treatment; Company Will Maintain Premium Listing on London Stock Exchange RICHMOND, Va., June 12, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV), a
3y agoINVVYIndivior Reaches Agreement with States' Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation ClaimsPR NewswireRICHMOND, Va., June 2, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV), a leading addiction treatment company, announced that its subsidiary, Indivior Inc. (the "Company"), has reached an agreement to resolve the
3y agoINVVYIndivior To Participate In Upcoming Investor ConferencesPR NewswireSLOUGH, England and RICHMOND, Va., May 25, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced that it will participate in the following investor events:
3y agoINVVYIndivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like FentanylPR NewswireIn the 12-month period ending in December 2022, over 79,000 people in the U.S. were reported to have died of an opioid overdose, of which 90% – approximately 72,000 – were linked to illicit synthetic opioids, mainly
3y agoINVVYIndivior Announces Q1 2023 Financial ResultsPR NewswireSLOUGH, U.K., and Richmond, Va., April 27, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced its financial results for the period ending March 31, 2023. The earnings release, investor presentation and webcast
3y agoINVVYIndivior To Participate In Bank of America Global Healthcare Conference 2023PR NewswireSLOUGH, UK and RICHMOND, Va., April 25, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced that it will participate in the following investor event:
3y agoINVVYIndivior Completes Acquisition of Opiant Pharmaceuticals, Inc.PR NewswireCombination Strengthens Indivior's Addiction Treatment and Science Portfolio RICHMOND, Va., March 2, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) ("Indivior" or the "Company") today announced that it
3y agoINVVYFY 2022 Financial Results AnnouncedPR NewswireSLOUGH, England and RICHMOND, Va., Feb. 16, 2023 /PRNewswire/ -- Indivior PLC (LSE: INDV) today announced 2022 Full Year Results. The earnings release, investor presentation, and webcast are available
3y agoINVVY OPNTIndivior Capital Markets Day Highlights Strategy for Shareholder Value Creation and Attractive Medium-Term Profitable Growth OutlookPR Newswire- Peak Annual Net Revenue Potential for SUBLOCADE® Increased to >$1.5 Billion - Attractive and Scalable Business Outlined – Expects Strong Net Revenue Growth and Operating Margin Expansion Over the Medium-term -
3y agoINVVY OPNTIndivior To Acquire Opiant PharmaceuticalsPR NewswireAcquisition Strengthens and Extends Indivior's Position as a Leader in Addiction Treatment Opiant Pipeline Anchored by OPNT003, an Opioid Overdose Treatment with Clinically Demonstrated Characteristics Well-Suited to
4y agoINVVYIndivior Announces Q3 2022 Financial ResultsPR NewswireSLOUGH, UK and RICHMOND, Va., Oct. 27, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced its financial results for the period ending September 30, 2022. The earnings release, investor presentation and webcast
4y agoINVVYIndivior Shareholders Approve Resolutions to Proceed with Additional U.S. ListingPR NewswireRICHMOND, Va., Sept. 30, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that at the General Meeting of Shareholders held earlier today, shareholders approved the resolution to proceed with an Additional Listing on a major U.S. stock exchan
4y agoINVVYIndivior To Participate in Upcoming Investor Healthcare EventsPR NewswireSLOUGH, United Kingdom and RICHMOND, Va., Sept. 7, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that it will participate in the following investor healthcare events:
4y agoINVVYIndivior Recognizes National Recovery Month, Commits to Helping Move People living with Opioid Use Disorder onto a Path to Hope and RecoveryPR NewswireRICHMOND, Va., Sept. 1, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) September is National Recovery Month, a time to educate about substance use disorder (SUD) and the effectiveness of evidence-based treatment and counseling, and let people know that re
4y agoINVVYIndivior Publishes Exploratory Study Showing That Access to Medication for Opioid Use Disorder Varies Across Organized Health Systems in the U.S.PR NewswirePublished in Drug and Alcohol Dependence Reports, the study shows that identifying and overcoming barriers to appropriate use of medications to treat opioid use disorder (OUD) is critical to address the opioid crisis RICHMOND, Va., Aug. 25, 2022 /PRN
4y agoINVVYIndivior Announces H1 and Q2 2022 Financial ResultsPR NewswireSLOUGH, U.K. and RICHMOND, Va., July 28, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced its financial results for the period ending June 30, 2022. The earnings release, investor presentation and webcast are available at www.indivior.com
4y agoINVVYIndivior Names Nina DeLorenzo Chief Global Impact OfficerPR NewswireRICHMOND, Va., June 16, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) announces the appointment of Nina DeLorenzo as Chief Global Impact Officer. DeLorenzo will serve on the Executive Committee and report to Indivior Chief Executive Officer Mark Crossley
4y agoINVVYIndivior Announces Seven Abstracts Accepted for Presentation at the 84th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD)PR NewswireRICHMOND, Va., June 9, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the acceptance of seven abstracts for presentation at the 84th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD) taking place June 11-15, 2
4y agoINVVYIndivior Announces First Patient Included in Aelis Farma's Phase 2b Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects With Moderate to Severe Cannabis Use DisorderPR NewswireSLOUGH, England and RICHMOND, Va., June 1, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) announces the enrollment of the first patient in the Phase 2b study of AEF0117 for the treatment of cannabis use disorder (CUD). This follows less than a year after
4y agoINVVYFor Mental Health Awareness Month, Indivior Offers Hope for Opioid Use Disorder Recovery Through One Man's Inspiring StoryPR NewswireRICHMOND, Va., May 19, 2022 /PRNewswire/ -- May is Mental Health Awareness Month, a time to increase understanding of the importance of mental health and to break the stigma associated with mental illness. Substance Use Disorder (SUD) is one type of ment
4y agoINVVYIndivior Lends Voice to Help Raise Awareness of Substance Use Disorder During Mental Health Awareness Month and National Fentanyl Awareness DayPR NewswireRICHMOND, Va., May 10, 2022 /PRNewswire/ -- May is Mental Health Awareness Month, a time to increase awareness of the importance of mental health and to break the stigma associated with mental illness. In addition, May 10th marks the first National Fenta
4y agoINVVYIndivior Announces Q1 2022 Financial ResultsPR NewswireSLOUGH, U.K. and RICHMOND, Va., April 28, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced its financial results for the period ending March 31, 2022. The earnings release, investor presentation and webcast are available at www.indivior.com
4y agoINVVYIndivior Statement on Nationwide Increases in Fentanyl-Related Mass-Overdose EventsPR NewswireExpanding access to medication to treat opioid use disorder is a critical part of the solution RICHMOND, Va., April 12, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today released the following statement regarding the US Drug Enforcement Administratio
4y agoINVVYIndivior Publishes Modeling Data Showing Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression in Chronic Opioid UsersPR NewswireData available online and in an upcoming print issue of JCI Insight, a peer-reviewed journal RICHMOND, Va., April 8, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) announces the publication of modeling data examining the competitive interaction between
4y agoINVVYIndivior to Commence Formal Shareholder Consultations on Additional US ListingPR NewswireRICHMOND, Va., March 31, 2022 /PRNewswire/ -- Indivior PLC, (LON: INDV) today announced that further to its announcement on February 16, 2022, it is commencing formal consultations with shareholders on the potential for an additional listing of Indivior
4y agoINVVYIndivior Announces Q4 and FY 2021 ResultsPR NewswireSLOUGH, England and RICHMOND, Va., Feb. 16, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced its financial results for the period ending December 31, 2021. The earnings release, investor presentation and webcast are available at www.indivio
4y agoINVVYResearch Indicates Sustained High Plasma Concentrations of Buprenorphine Reduce Fentanyl-Induced Respiratory Depression in Opioid-Tolerant ParticipantsPR NewswireRICHMOND, Va., Jan. 27, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the publication of data from a clinical pharmacology study designed to assess the ability of buprenorphine to reduce respiratory depression and apnea associated with es
5y agoINVVYIndivior Presents Study at the 2021 National Commission on Correctional Healthcare Conference on Factors Impacting Medications for Opioid Use Disorder Treatment Approaches in Criminal Justice-Involved PopulationsPR NewswireRICHMOND, Va., Nov. 1, 2021 /PRNewswire/ -- Indivior PLC (LON: INDV) announced today the presentation of data at the National Commission on Correctional Healthcare Conference (NCCHC) from a mixed methods study examining opioid use disorder (OUD) treatme
5y agoINVVYIndivior to Present New Data on Opioid Use Disorder at CSAM-SMCA 2021 Scientific ConferencePR NewswireRICHMOND, Va., Oct. 21, 2021 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the presentation of new data from multiple posters and presentations at the Canadian Society of Addiction Medicine – La Société Médicale Canadienne sur L'add
5y agoINVVYIndivior Presents New Data at the College on Problems of Drug Dependence (CPDD) 2021 Annual ConferencePR NewswireRICHMOND, Va., June 24, 2021 /PRNewswire/ -- Indivior PLC (LON: INDV) announces the presentation of new data from three posters and one late-breaking oral presentation at the College on Problems of Drug Dependence (CPDD) 83rd Annual Scientific Virtual M
5y agoINVVYIndivior Extends Leadership Position In Substance Use Disorder Treatment With Exclusive Agreement For Leading Asset Targeting Cannabis-Related DisordersPR NewswireRICHMOND, Va., June 8, 2021 /PRNewswire/ -- Indivior PLC, (LON: INDV) today announced that it is extending its leadership position in substance use disorder ("SUD") treatment by expanding into the under treated cannabis-related disorders, including cann
5y agoINVVYStudy Examining Impact of COVID-19 Pandemic on Opioid Use Disorder (OUD) Finds Greater Barriers to Care During PandemicPR NewswireRICHMOND, Va., April 22, 2021 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced findings from a qualitative study examining the impact of COVID-19 on opioid use disorder (OUD) management and medication for opioid use disorder (MOUD) access in the